Emma Walmsley

Emma Walmsley, one of pharma’s most powerful bosses and one of just a handful of female CEOs in the U.K.’s FTSE 100, is entering the ninth year of her ambitious turnaround mission at GSK, driving the company forward in discoveries related to cancer and antimicrobial resistance, while doubling down on AI. In 2024 GSK doubled sales of its cancer treatments, taking total company revenue to $41.7 billion.